Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Circ Heart Fail. 2019 Apr;12(4):e005565. doi: 10.1161/CIRCHEARTFAILURE.118.005565

Figure 7: SAC/VAL is more efficient at inactivating Rho than is SAC or VAL alone in CF derived from heart failure patients.

Figure 7:

A. Pulldown of Rho with beads conjugated to the Rho-binding domain of rhotekin (specific for activated Rho) reveals that for all four patient-derived primary CF lines tested, the combination of Sacubitrilat and valsartan significantly ameliorates Rho activation. B-E. Quantification of data for each line isolated as shown in (A). n = 3 each condition. One-way ANOVA for each patient-derived line, Tukey’s multiple comparisons test. * = p < 0.05 relative to vehicle. & = p < 0.05 relative to TGF-β1/AngII/ANF.